Welcome to The Denice M Cunningham Foundation
Measuring neurofilaments in brain and spinal fluid appears to be a reliable way of confirming an ALS diagnosis, Belgian and German researchers report. This finding is important because it takes an average of a year from the appearance of the first symptoms before doctors can diagnose the disease. The discovery could shorten this time. The neurons […]
Read More »MAY 15, 2017 BY MAGDALENA KEGEL A gene therapy aimed at strengthening the connection between motor neurons and muscle prevented nerve degeneration and increased the life span of mice with amyotrophic lateral sclerosis (ALS), a study showed. Since researchers believe that neurodegeneration in ALS starts at the junction between nerves and muscle, the findings suggest that […]
Read More »ALS News Today, May 18, 2017, written by Joana Fernandes, PHD. Mutations in the UBQLN4 gene may contribute to the development of amyotrophic lateral sclerosis (ALS), according to recent research. The study, “A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis,” was published in the journal eLife. Over the years, researchers have identified numerous genes linked to […]
Read More »Monday May 8, 2017 — A new drug was approved by the Federal Drug Administration on Friday May 5, 2017 – the first drug to treat ALS approved since 1995. The only other drug on the market today is Riluzole (or, Rilutek, Sanofi-Aventis U.S. LLC) which purports to extend the lives of ALS patients by […]
Read More »
DMC Fund RSS Feed